Yazar "Sert, F." seçeneğine göre listele
Listeleniyor 1 - 20 / 20
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?(Elsevier, 2021) Sert, F.; Cosgun, G.; Yalman, D.; Ozkok, S.Purpose. - To define the factors which may be related to brain metastasis (BM) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who developed brain metastases after definitive treatment. Patients and methods. - A total of 208 patients with LA-NSCLC, without BM who received definitive radiotherapy (RT) or RT + chemotherapy (CT) between January 2005 and January 2016 were evaluated retrospectively. Platelet, neutrophil, lymphocyte counts, LDH, CRP, Hb levels, neutrophil-to-lymphocyte radio (NLR), platelet-to-lymphocyte radio (PLR), advanced lung cancer inflammation index (ALI) and FDG-PET/CT parameters (SUVmax of the primary tumor and mediastinal lymph nodes), and patient characteristics were evaluated for brain metastasis free survival (BMFS). Results. - Median follow-up duration was 25 months (range: 3-130 months). Cut-off values for platelet, NLR, PLR, LDH, CRP, and Hb were 290 x 103/mu L, 2.6, 198, 468 IU/L, 2.5 mg/dL, and 11.5 g/d1. We defined each parameter as low or high according to the cut-off values. 56 patients (26.9%) developed brain metastases during follow-up. In univariate analysis, high NLR (P=0.001), PLR (P=0.037), LDH (P = 0.028), CRP (P = 0.002) values, value >= 7.5 for lymph nodes (P = 0.005) and low ALI value (P = 0.002) were poor prognostic factors for BMFS. In multivariate analysis, high NLR (P= 0.022), PLR (P= 0.017), CRP (P= 0.006), stage >= IIIB disease (P< 0.001), multi-stational N2 disease (P= 0.036), adenocarcinoma histology (P< 0.001) and SUVmax value >= 7.5 (P = 0.035) were poor prognostic factors for BMFS. Conclusions. - High NLR, PLR, LDH, CRP values, SUVmax values for lymph nodes, and low ALI which indicates high tumor burden were additional prognostic factors besides stage, histology, and lymph node status. (C) 2020 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.Öğe Determining the Patterns of Care to Adolescent and Young Adult Cancer Patients in Turkey: Turkish Oncology Group Study(Elsevier Science Inc, 2020) Sert, F.; Kamer, S.; Guney, Y. Yukselen[No abstract available]Öğe The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study(Elsevier Ireland Ltd, 2017) Ozyigit, G.; Onal, C.; Igdem, S.; Alicikus, Z. Arican; Iribas, A.; Akin, M.; Yalman, D.; Cetin, I.; Aksu, M. G.; Atalar, B.; Dincbas, F.; Aydin, B.; Sert, F.; Yildirim, C.; Gorken, I. B.; Agaoglu, F. Y.; Korcum, A. F.; Ozkok, S.; Darendeliler, E.; Akyol, F.Öğe Geriatric Stage III NSCLC: Which scoring systems could guide us better to predict treatment outcome?(Elsevier Ireland Ltd, 2022) Sert, F.; Farzam, F.; Yalman, D.; Ozkok, S.[No Abstract Available]Öğe Global Plan Check: A Software to Register and Analyze Dose Distribution Independent from Treatment Planning Systems(Elsevier Science Inc, 2023) Sert, F.; Hidimoglu, C.; Koylu, M.[No abstract available]Öğe HPV Infection and Immunohistochemical Analysis of P16, P53, and PD-L1 Expression as Prognostic Biomarkers in Squamous Cell Anal Cancer Patients Receiving Definitive Radiotherapy/Chemoradiotherapy(Elsevier Science Inc, 2023) Topuz, B. Balcı; Sert, F.; Sezak, M.; Soylu, M.; Yalman, D.; Ozkok, S.[No abstract available]Öğe IRRADIATION OF SUBVENTRICULAR ZONE IN GLIOBLASTOMA: ITS IMPACT ON TUMOR PROGRESSION AND SURVIVAL(Oxford Univ Press Inc, 2016) Sert, F.; Hoca, S.; Kamer, S.; Anacak, Y.Öğe Irradiation of Subventricular Zone in Glioblastoma: Its Impact on Tumor Progression and Survival(Elsevier Ireland Ltd, 2017) Sert, F.; Hoca, S.; Kamer, S.; Anacak, Y.Öğe Lateral ventricule invasion and radiation dose to subventricular zone: Their impact to the treatment outcomes of glioblastoma(Ijrr-Iranian Journal Radiation Res, 2018) Sert, F.; Hoca, S.; Kamer, S.; Anacak, Y.Background: This study was conducted to evaluate the recurrence patterns of GBM in regard to its contact with LVs, the relation between radiation doses to subventrivular zone (SVZ). Materials and Methods: Between 2012 and 2014, 80 adult patients with GBM were included this trial. Median follow-up period was 15 months. Median tumor size was 4.5 cm (1.3-8 cm), where 58% of the patients had a tumor larger than 4 cm. All of the lesions were located supratentorial part of brain. Tumors were classified based on whether the mass involved the SVZ and/or LVs. Reccurrence patterns and treatment outcomes were compared. Results: Tumor progression occurred in 60 (75%) of the patients. Of those 31 (51.6%) were in-field. Median progression-free survival (PFS) and median overall survival (OS) times were 11 and 15 months, respectively. On multivariate analysis, the negative prognostic factors were maximal surgical resection (p=0.027), LV-invading tumor (p=0.001) and p53 positivity (p=0.034) for PFS. It was found that the patients receiving >50 Gy to iSVZ dose (p=0.024) or >40 Gy to cSVZ dose (p=0.002) or >40 Gy to bSVZ dose (p=0.028) or >50 Gy to bSVZ dose (p=0.008) tended to have more recurrences. Both in-field and out-field recurrences were not affected by higher radiation doses. Conclusion: LVs invading and/or location close to the SVZs can be considered as an important prognostic factor in terms of decreased PFS and OS rates. Additionally both SVZs sparing and dose escalation to SVZs approaches are required to be evaluated in further researches.Öğe Lymphopenia and accidental splenic doses for locally advanced gastric cancer(Elsevier Ireland Ltd, 2019) Sert, F.; Yalman, D.; Ozkok, S.Öğe Molecular Resistance Mechanisms in the Treatment of Locally Advanced Cervical Cancer: HIF-1 alpha? ERCC1?(Elsevier Ireland Ltd, 2022) Sert, F.; Serin, G.; Ozturk, M.; Zekioglu, O.; Alanyali, S.; Ozsaran, Z.[No Abstract Available]Öğe The Pain Relief and Recalcification Results of Radiation Therapy in Plasma Cell Tumors(Elsevier Science Inc, 2017) Sert, F.; Kamer, S.; Soyer, N.; Saydam, G.; Anacak, Y.Öğe The Pain Relief and Recalsification Results of Radiotherapy in Plasma Cell Tumors(Elsevier Ireland Ltd, 2018) Sert, F.; Kamer, S.; Saydam, G.; Argin, M.; Anacak, Y.Öğe Prognostic Factors Affecting Brain Metastasis-Free Survival in Non-Small Cell Lung Cancer Patients(Elsevier Science Inc, 2019) Sert, F.; Yalman, D.; Cosgun, G.; Ozkok, S.[No abstract available]Öğe Prognostic Value of Hypoxia for Locally Advanced Hypopharynx Squamous Cell Carcinoma(Elsevier Ireland Ltd, 2019) Sert, F.; Serin, G.; Veral, A.; Esassolak, M.Öğe Prognostic Value of Volumetric PET Parameters in Patients with Locally Advanced Rectal Cancer(Elsevier Ireland Ltd, 2019) Sert, F.; Oral, A.; Savas, R.; Yalman, D.; Ozkok, S.Öğe Radiation Therapy and Chemotherapy Results in Elderly Patients With Stage III Non-Small Cell Lung Cancer: Turkish Thoracic Radiation Oncology Group Study(Elsevier Science Inc, 2016) Akyurek, S.; Ozdemir, B. S.; Sert, F.; Yalman, D.; Yavas, G.; Cengiz, M.; Bakkal, H.; Yoney, A.; Kose, K.Öğe Radiotherapy for elderly laryngeal carcinoma patients: A Single Centre Experience from Turkey(Elsevier Ireland Ltd, 2018) Sert, F.; Kaya, I.; Ozturk, K.; Esassolak, M.Öğe REGIONAL RECURRENCE RATES OF STAGE I ENDOMETRIAL CARCINOMA PATIENTS TREATED WITH ADJUVANT BRACHYTHERAPY(Lippincott Williams & Wilkins, 2017) Alanyali, S.; Sert, F.; Gocen, F.; Temel, O.; Ozsaran, Z.; Yildirim, N.; Solmaz, U.; Gokcu, M.; Akman, L.; Terek, C.; Ozsaran, A.; Sanci, M.; Yildiz, H. I.; Ozkok, S.; Aras, A.Öğe REGIONAL RECURRENCE RATES OF STAGE I ENDOMETRIAL CARCINOMA PATIENTS TREATED WITH ADJUVANT BRACHYTHERAPY(Lippincott Williams & Wilkins, 2017) Alanyali, S.; Sert, F.; Gocen, F.; Temel, O.; Ozsaran, Z.; Yildirim, N.; Solmaz, U.; Gokcu, M.; Akman, L.; Terek, C.; Ozsaran, A.; Sanci, M.; Yildiz, H. I.; Ozkok, S.; Aras, A.
